Accredited Investors Inc. Has $217,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Accredited Investors Inc. cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 901 shares of the medical instruments supplier’s stock after selling 66 shares during the quarter. Accredited Investors Inc.’s holdings in Becton, Dickinson and Company were worth $217,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the third quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company during the 3rd quarter worth approximately $33,000. Tompkins Financial Corp boosted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC boosted its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Opal Wealth Advisors LLC bought a new position in Becton, Dickinson and Company during the second quarter worth $45,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.9 %

Shares of Becton, Dickinson and Company stock opened at $225.15 on Monday. The stock has a market capitalization of $65.08 billion, a PE ratio of 37.90, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The stock has a 50 day moving average price of $236.30 and a two-hundred day moving average price of $235.00. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the previous year, the business posted $3.42 EPS. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.85%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 63.97%.

Wall Street Analyst Weigh In

A number of analysts have commented on BDX shares. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.